Risk of epidemic meningitis in Africa: a cause for concern.
D000900:Anti-Bacterial Agents / Q000600:supply & distribution / Q000627:therapeutic use; D002050:Burkina Faso / Q000453:epidemiology; D002443:Ceftriaxone / Q000627:therapeutic use; D002701:Chloramphenicol / Q000600:supply & distribution / Q000627:therapeutic use; D004196:Disease Outbreaks / Q000517:prevention & control; D005002:Ethiopia / Q000453:epidemiology; D006801:Humans; D008302:Mali / Q000453:epidemiology; D008585:Meningitis, Meningococcal / Q000188:drug therapy / Q000453:epidemiology*; D022401:Meningococcal Vaccines / Q000627:therapeutic use; D038381:Neisseria meningitidis, Serogroup A; D009548:Niger / Q000453:epidemiology; D009549:Nigeria / Q000453:epidemiology; D013397:Sudan / Q000453:epidemiology
D000900:Anti-Bacterial Agents; D022401:Meningococcal Vaccines; D002701:Chloramphenicol; D002443:Ceftriaxone